In conclusion, TSRP can reshape the TME by inhibiting the PI3K/Akt/mTOR pathway, thereby impeding bone metastasis of NSCLC with PI3K mutation and primary immune checkpoint resistance. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.